Zhejiang Ausun Pharmaceutical (603229.SH) has received the approval notice for the market application of Atorvastatin Sodium Active Pharmaceutical Ingredient.
Ouxiang Pharmaceutical (603229.SH) announced that the company has recently received the "Approval Notice for the Market Application of Atorvastatin Sodium Active Pharmaceutical Ingredient" issued by the National Medical Products Administration.
Zhejiang Ausun Pharmaceutical (603229.SH) announced that it has recently received approval from the National Medical Products Administration for the production and sale of the chemical raw material Fluorfenatate Sodium.
Fluorfenatate Sodium is a fully synthetic hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, used in the treatment of primary hypercholesterolemia, mixed dyslipidemia, and can also be used for lipid regulation in patients with coronary heart disease and other high-risk patients to delay the progression of atherosclerosis, reduce the risk of adverse cardiovascular events such as myocardial infarction and ischemic stroke.
Related Articles
China Construction Bank Corporation (00939): Sun Xiaokun officially assumes office as an executive director.
YUNJI (02670) spent 4.3844 million Hong Kong dollars on June 2nd to repurchase 13,900 shares.
SHUANGDENG (06960) accepted the 2026 stock option plan.
China Construction Bank Corporation (00939): Sun Xiaokun officially assumes office as an executive director.
YUNJI (02670) spent 4.3844 million Hong Kong dollars on June 2nd to repurchase 13,900 shares.
SHUANGDENG (06960) accepted the 2026 stock option plan.
